期刊文献+

急性冠脉综合症患者死亡率与内皮细胞激活因子的相关性研究 被引量:1

Correlation of Mortality in Patients with Acute Coronary Syndrome and Endothelial Cell Active Markers
下载PDF
导出
摘要 目的:探讨急性冠脉综合症(ACS)患者死亡率与内皮细胞激活因子的相关性。方法:检测未接受冠状动脉介入治疗的339例ACS患者血浆中的血浆血管性血友病因子(VWF)、血浆血管性血友病因子前肽(VWF:pp)和骨保护素(OPG),观察其与住院期间死亡的关系。结果:住院期间死亡(死亡组)46例,存活(存活组)293例。死亡组VWF:pp明显高于生存患者组(P<0.05);高浓度OPG者的死亡率明显高于低浓度OPG者(P<0.05)。结论:未接受冠状动脉介入治疗的ACS患者中,内皮细胞功能的激活和紊乱与住院期间死亡率相关。 Objective:To investigate the relationship between endothelial cell activation markers and mortality in patients with acute coronary syndrome (ACS). Methods: Plasma levels of endothelial cell activation markers such as yon Willebrand factor (VWF), yon Willebrand factor propeptide (VWF : pp) and osteoprotegerin (OPG) were measured of 339 patients with ACS who underwent expectant treatment. The relationship between the endothelial cell activation markers and the mortality were observed during the in-hospital periods. Results: There were 46 deaths (death group) and 293 survivors (survival group) during the in-hospital periods. Median values of VWF and VWF: pp were significantly higher in the death group than those in the survival group (both P〈0.05). The mortality was significantly higher in patients with high OPG than that in patients with low OPG (P〈0.05). Conclusion: In patients with ACS undergoing expectant treatment, increased endothelial cell activation and dysfunction is associated with mortality during the in-hospital periods.
出处 《岭南急诊医学杂志》 2013年第2期87-89,共3页 Lingnan Journal of Emergency Medicine
关键词 急性冠脉综合症 内皮细胞激活因子 死亡率 相关性 acute coronary syndrome endothelial cell activation factor mortality Correlation
  • 引文网络
  • 相关文献

参考文献7

  • 1Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST- segment elevation acute coronary syndromes [J]. Eur Heart J, 2007,28 : 1598.
  • 2Eagle KA, Lim M J, Dabbous OH, et al. A validated prediction model for a11 forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry [J]. JAMA, 2004, 291 : 2727.
  • 3Yamashita A, Sumi T, Goto S, et al. Detection of yon Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction [J]. Am J Cardiol, 2006,97 : 26.
  • 4Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis [J ]. J Clin Invest, 2005, 115 : 3378.
  • 5Spiel AO, Gilbert JC, yon Jilma B. Willebrand factor in cardiovascular disease: focus on acute coronary syndromes[J]. Circulation, 2008,117 : 1449.
  • 6Derhaschnig U, Jilma B. Assessment of platelets and the endothelium in patients presenting with acute coronary syndromes-is there a future? [J]. Thromb Hae, 2009, 102 - 1144.
  • 7Omland T, Ueland T, Jansson AM, et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes[J]. J Am Coil Cardiol, 2008,51 : 627.

同被引文献11

  • 1Retraction. The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular taehy- cardia in patients with acute coronary syndrome[J]. Clin Cardiol, 2013, 36(8): 494.
  • 2LIU Y, SU Q, LI L. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome underg- oing percutaneous coronary intervention: a recta-analysis of nine randomized controlled trials [ J ]. Clin Cardiol, 2013, 36 (12) : E41-E48.
  • 3ARCA M, NATOLI S, MICHELETTA F, et al. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy [J ]. Free Radie Biol Med, 2007, 42(5) : 698-705.
  • 4DAI S, YANG Q, YUAN K, et al. Non-high-density lipoprotein cholesterol: distribution and prevalence of high serum levels in children and adolescents: United States National Health and Nutrition Examination Surveys, 2005-2010[J]. J Pediatr, 2013, 164(2) : 247-153.
  • 5MILLER M, STONE N J, BALLANTYNE C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association [ J ]. Circulation, 2011, 123 (20) : 2292-2333.
  • 6SMITH S J, ALLEN J, BLAIR S N, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atheroselerotic vaseular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute [J]. Circulation, 2006, 113(19) : 2363-2372.
  • 7BEZIN J, PARIENTE A, LASSALLE R, et al. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France [ J ]. Eur J Clin Pharmacol, 2013, 70(4) :429-436.
  • 8BENJO A M, EL-HAYEK G E, MESSERLI F, et al. High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events : A meta-analysis of randomized controlled trims [ J ]. Catheter Cardiovasc Interv, 2013 Nov 23. doi: 10.1002/ccd.25302. [Epub ahead of print].
  • 9OJEIFO O, WIVIOTT S D, ANTMAN E M, et al. Concomitant Administration of Clopidogrel With Statins or Calcium Channel Blockers: Insights From the TRITON-TIMI 38 (Trim to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) TriM[J]. JACC Cardiovasc Interv, 2013, 6(12) : 1275- 1281.
  • 10WAKELEE H A, TAKIMOTO C H, LOPEZ-ANAYA A, et al. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarutene plus chemotherapy in patients with advanced non-small cell lung cancer [J]. Cancer Chemother Pharmacol, 2012, 69 ( 2 ) : 563 - 571.

引证文献1

二级引证文献3

;
使用帮助 返回顶部